**Supplementary Data:** Jianhui Zhu, Aaron M Gusdon, Huseyin Cimen, Bennett Van Houten, Emine Koc & Charleen T. Chu. *Impaired mitochondrial biogenesis contributes to depletion of functional mitochondria in chronic MPP+ toxicity: dual roles for ERK1/2* **Cell Death and Disease** (2012) 3, e ; doi:10.1038/cddis.2012.46



Fig S1

Fig S1. Progressive, dose-dependent cell death in a 2 wk model of MPP+ toxicity. Differentiated SH-SY5Y cells were treated three times a week with the indicated doses of MPP+ (A). Mitochondrial membrane potential was analyzed by JC-1 staining (B). Quantitative analysis of mitochondrial contours showed chronic MPP treatment significantly increased the percentage of both shortened/fragmented and giant mitochondria (C). These mitochondria generally showed significant decreases in perimeter (D) with increased circularity (E). \*\* P < 0.01, \*P < 0.05, MPP<sup>+</sup> vs Ctrl.

Fig S2



**Fig S2.** Representative images showed that  $250\mu$ M MPP<sup>+</sup> x 2 weeks increased the size of MDC granules compared with vehicle-treated control (A) (scale bar:  $20\mu$ m). Quantitative analysis reveal a decrease in numbers of granules per cell after treatment, but with an increase in size (B, \*\* P < 0.01 MPP<sup>+</sup> vs Ctrl. **†** P < 0.01 500uM MPP<sup>+</sup> vs 250uM MPP<sup>+</sup>) consistent with lysosomal activation. RNAi knockdown of either Atg8 (LC3B) or Atg7 conferred partial protection from MPP<sup>+</sup> toxicity (C, \* P < 0.05 versus siCtrl). Atg7 siRNA attenuates the MPP<sup>+</sup> induced loss of the mitochondrial proteins PDH and mitochondrial p60 (D, \*p<0.05 vs siCtrl-Veh, **†** p<0.05 vs siCtrl-MPP. n=4).

Fig. S3



Fig. S3. Western blot data showed that administration of U0126 on a chronic basis mimicking rescue conditions caused an increase in expression of the dopamine transporter (DAT) and decreased expression of vesicular monoamine transporter 2 (Vmat 2) protein levels (A). Mitochondrial respiration assay showed that U0126 had no effect on the acute MPP+-induced inhibition of oxygen consumption (B). Inhibiting lysosomal activity by E64D partially, but significantly, reversed the NDUFA9 reduction in MPP<sup>+</sup> treated cells (250  $\mu$ M x 2wks) (C,D). \*\* p < 0.01, MPP vs ctrl. † p<0.01 MPP<sup>+</sup>+E64D vs MPP<sup>+</sup>+Veh. A cocktail containing proteasomal (2.5 $\mu$ M lactacystin) and lysosomal [20 $\mu$ M Pepstatin A(Cat D); 5  $\mu$ M CA074ME (Cat B) and 10  $\mu$ M E64D-Cat B,L] inhibitors moderately reduced the decrease in mitochondrial respiratory complex I, III and IV subunits elicited by MPP<sup>+</sup> treatment (E). The decrease in TFAM and NDUFA9 levels are also reduced by siRNA knockdown of the mitochondrial LON peptidase 1 (F). Densitometric analysis of western blots show that siRNA to ERK1/2 attenuates the loss in TFAM and the indicated subunits of the mitochondrial respiratory complexes (G, \*p<0.05 vs siCtrl-Veh, **†** p<0.05 vs siCtrl-MPP, n=4)





Fig. S4. Preventing ERK1/2 activation through molecular or pharmacologic inhibition of MEK reverses MPP+ induced mitochondrial injury. Overexpressing DN-MEK1 prevented the decrease in mitochondrial complex I and IV subunits in MPP<sup>+</sup> treated cells (A, B. \*p<0.05 vs Vector-Veh,  $\dagger$  p<0.05 vs Vector-MPP, n=5 for B). Representative electron micrographs of control cells (C) compared to cells treated with 250µM MPP<sup>+</sup> for 1 week (D), for 2 weeks (E) or for 2 weeks with MPP+ with addition of 5µM U0126 during the second week only (F). (scale bar: 500nm)



Fig. S5. Quantitative analysis of Western blots showed that MPP<sup>+</sup> treatment (250 $\mu$ M, 2wks) did not significantly change the total PGC-1 $\alpha$  and NRF1 protein levels (A,B). The degree of PGC-1 $\alpha$ colocalization with immunostained mitochondria was analyzed using NIH Image J (C). \*\* p< 0.01 compared with other groups. The mRNA levels of TFAM and PGC-1 $\alpha$ , as analyzed by qRT-PCR (normalized to GAPDH), showed no significant changes in MPP<sup>+</sup> (250 $\mu$ M x 1wk)-treated cells +/- U0126 (D). TFAM over-expression protected against MPP+ induced alterations in mitochondrial complexes (E, \*p<0.05 vs Vector-Veh, **†** p<0.05 vs Vector-MPP, n=4)





Fig S6. Acute 2.5mM MPP+ treatment for 24hr inhibits synthesis of mtDNA coded respiratory subunits; however, inhibiting MEK-ERK1/2 signaling had no significant effect on mitochondrial translation in this high-dose acute model. Coomassie Brilliant Blue stain was used as a loading control.